Nurix Therapeutics, Inc. 4

Nurix Therapeutics CLO Christine Ring exercised 28,935 stock options and sold 28,935 Nurix common shares on 2026-06-25 under a Rule 10b5-1 plan, ending with 13,579 shares owned.

On June 25, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised two employee stock options and sold a portion of the resulting shares under a pre-arranged Rule 10b5-1 trading plan. She exercised 13,333 options at $7.26 and 15,602 options at $8.72, acquiring a total of 28,935 shares of common stock, and then sold 28,935 shares at a weighted average price of $20.0624 per share (within a $20.00–$20.40 range). The option exercises appear cashless (Form 4 shows $0 for the derivative disposition legs), with the economic gain realized through the sale spread between the exercise prices and the sale price. Following these transactions, Ring beneficially owns 13,579 shares of Nurix common stock directly, with no remaining balance in the exercised options and continued vesting on her remaining option grant.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

sec

Accession

0001817199-26-000022

Alert Tier

6